New triple-action diabetes drug shows major weight loss results

Experimental drug retatrutide shows promise for type 2 diabetes and obesity by targeting three hormone pathways. A phase 3 trial revealed participants achieved up to 15.3% body weight loss and improved blood sugar levels over 40 weeks. While results outpace existing treatments, further studies are required to confirm long-term safety and effectiveness before clinical adoption.